findmyKOL
Clinical trialNCT01176565TerminatedPhase 3Interventional

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

SponsorUniversity of MinnesotaEnrollment1,000Intracerebral Hemorrhage
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The specific aims of this study are to: 1. Definitively determine the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of patients with death and disability (mRS 4-6) at 3 months among subjects with ICH who are treated within 4.5 hours of symptom onset. 2. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the subjects' quality of life as measured by EuroQol at 3 months. 3. Evaluate the therapeutic benefit of the intensive treatment relative to the standard treatment in the proportion of hematoma expansion (defined as increase from baseline hematoma volume of at least 33%) and in the change from baseline peri-hematoma volume at 24 hours on the serial computed tomographic (CT) scans. 4. Assess the safety of the intensive treatment relative to the standard treatment in the proportion of subjects with treatment-related serious adverse events (SAEs) within 72 hours.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

171 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • University of Alberta

    Edmonton, Alberta, Canada

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, Canada

China
  • the Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • the Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Baotou Central Hospital

    Baotou, China

  • Beijing Tiantan Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Datong Third People'S Hospital

    Datong, China

  • the First Hospital of Shanxi Medical University

    Taiyuan, China

  • the First People'S Hospital of Taizhou

    Taizhou, China

  • Tianjin Fourth Central Hospital

    Tianjin, China

  • Renmin Hospital of Wuhan University

    Wuhan, China

  • Wuhan Brain Hospital

    Wuhan, China

  • People'S Hopital of Zhengzhou

    Zhengzhou, China

Germany
  • Charité Universtity Medicine Berlin

    Berlin, Germany

  • University of Bonn

    Bonn, Germany

  • University Hospital Dresden

    Dresden, Germany

  • Clinic Frankfurt Hoechst

    Frankfurt, Germany

  • University Hospital Halle

    Halle, Germany

  • University Hospital Heidelberg

    Heidelberg, Germany

  • University Hospital Leipzig

    Leipzig, Germany

  • University Hospital Mannheim

    Mannheim, Germany

  • University Hospital Meunster

    Münster, Germany

  • University of Tubingen

    Tübingen, Germany

Japan
  • Nagoya Medical Center

    Nagoya, Aichi-ken, Japan

  • Nakamura Memorial Hospital

    Sapporo, Hokkaido, Japan

  • Saiseikai Yokohamashi Tobu Hospital

    Kanagawa, Kanagowa, Japan

  • Saiseikai Kumamoto Hospital

    Kumamoto, Kumamoto, Japan

  • Kyushu Medical Center

    Fukuoka, Japan

  • Gifu University Hospital

    Gifu, Japan

  • St. Marianna - Toyoko

    Kawasaki, Japan

  • St. Marianna University Hospital

    Kawasaki, Japan

  • Kobe City Medical Center General Hospital

    Kobe, Japan

  • Kawasaki Medical School

    Okayama, Japan

  • National Cerebral and Cardiovascular Center

    Osaka, Japan

  • Kohnan Hospital

    Sendai, Japan

  • Keio University Hospital

    Tokyo, Japan

  • Kyorin University

    Tokyo, Japan

  • Saiseikai Central Hospital - Tokyo

    Tokyo, Japan

  • Toranomon Hospital

    Tokyo, Japan

131 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Intravenous nicardipine hydrochloride
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 May 2011
Primary completion
21 Dec 2015
Completion
8 Mar 2016
Last update posted
25 Apr 2017
Registered enrollment
1,000
Registry id
NCT01176565
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.